Cagrilintide vs GLP-1s: A Different Appetite Pathway?
Topics discussed
Sponsorships: Accenture and LinkedIn Hiring Pro
Introduction to Cagrelentide and GLP-1 context
The biological case for combination therapy
Amylin physiology and Cagrelentide mechanism
Comparing Cagrelentide and GLP-1 pathways
Standalone Cagrelentide Phase 2 trial data
Cagri-Sema combination: Phase 3 results and cautions
Unstudied stacks: Cagri with Terzepatide and Retrutide
Risks of Cagrelentide plus Terzepatide
Risks of Cagrelentide plus Retrutide
Why excessive satiety suppression is not always better
Social media reports on Cagrelentide usage
Body composition, muscle loss, and function
Safety profile and adverse events
Open questions and unknowns in the data
Regulatory status and product quality concerns
Mechanism recap and practical usage advice
Sponsor segment: Peptide Solutions
Conclusion and final takeaways
Listen ad-free on Castria